Financial Daily from THE HINDU group of publications
Friday, Oct 21, 2005


Group Sites

Industry & Economy - Pharmaceuticals
Corporate - Corporate Disputes

Avian flu drug: Who owns the patent?

P.T. Jyothi Datta

Mumbai , Oct 20

AS the world watches how Roche supplies its anti-flu medicine Tamiflu to countries faced with the bird-flu problem, a patent twist threatens to add to the existing controversy around the drug and its availability.

Gilead Sciences, the developer of Tamiflu, is believed to have terminated its agreement with Roche, which has the exclusive marketing right on the drug. And generic manufacturers like Cipla, looking to make similar versions of Tamiflu, are now taking a close look at the intricacies of who indeed holds the patent on the drug.

According to a note from Gilead Sciences Inc, dated June 2005, the company has "delivered a notice of termination to F. Hoffmann-La Roche Ltd (Roche) for material breach of the parties' 1996 Development and Licence Agreement for Tamiflu (oseltamivir phosphate), an antiviral pill for the treatment and prevention of influenza. Through this action, Gilead is seeking to terminate the 1996 agreement, which would result in the rights to Tamiflu held by Roche reverting to Gilead."

The Cipla Joint Managing Director, Mr Amar Lulla, told Business Line: "It is a complex issue. We have asked our lawyers to look at whether Roche has a valid licence on the drug. It is a fundamental question."

Roche top-brass in India, when contacted by Business Line, did not clarify on the issue.

Trying to make sense of the development, a patent attorney said that termination could be limited to certain markets, but Gilead has in fact filed for patents in India and other developed markets.

Significantly, Gilead's June note states: "Despite our repeated communication of concerns over the last several years, Roche has not adequately demonstrated the requisite commitment to Tamiflu since its launch in the US nearly six years ago, nor has it allocated the necessary resources to realise the potential of the product as a treatment and preventive for influenza," said Mr John C. Martin, President and Chief Executive Officer, Gilead Sciences.

But all that has changed following the latest panic surrounding bird-flu. As countries stock-piled Tamiflu medicine, fears of a shortage fanned across different countries and Roche came under considerable pressure to scale-up its production.

Eventually Roche agreed to loosen its grip on Tamiflu, by expressing its willingness to talk to generic producers who could make copies of Tamiflu. Just that the generic makers now want to know, who issues a production license on Tamiflu, Roche or Gilead?

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Tata Safari Dicor

Stories in this Section
BMC poor at handling monsoon crisis, say Mumbai consumers

Fresh cyclonic circulation over Bay by weekend
Awareness drive on renewable energy sources
`Company Law Board has powers to deal with contempt'
Global benchmarks in manufacturing — Indian arms of MNCs show the way
Diabetes rampant in Hyderabad: Study
Bangalore infrastructure issues — Narayana Murthy quits as BIAL Chairman
JMC bags TN road project
KSTC comes out of red
Crude oil output dips by 7.3% in Sept
IOC pre-qualifies to bid for Kenya-Uganda pipeline
Cabinet gives in-principle nod for IBP-IOC merger
Avian flu drug: Who owns the patent?
The green touch
Industry upbeat on Tata Steel's expansion
Steel cos likely to sustain growth on robust volumes
TN Govt seeks cash transaction tax exemption
AP records 16 pc growth in revenue collections
SMERA to rate SBI clients
SIDBI, Srei tie up to lend to SMEs
SBI signs pact with Crisil
`Alliance for Water' meet in Mangalore on Sunday
DD to telecast Sri Lanka, S. Africa series
`DD best possible option'
Sports channels have to share telefeed with Prasar Bharati — Cabinet clears uplinking, downlinking policy
Zee not eligible: BCCI
Sahara One plans to go for bouquet sales — Filmy channel to be launched soon
XLRI students to get taste of `real India'
Floating varsity arrives in Chennai
End of the road
How to use ACs with energy-efficiency
Lifeline Group opens new multi-speciality hospital
AP: Cabinet sanctions Rs 50 cr for VIMS
LIC to grow income from properties
`Rising demand may force import of paper'
Kinfra plans printing park
Putting lustre back to tinplate packaging
TRF: Hiring more to stay on growth path
Bengal to be focus State at Delhi fair
BASF to organise Kids Lab in Delhi
FIs urged to design model that allows community collateral
I-T search operations at IL&FS
High margins trigger increase in soya oil imports
Call to rationalise trade policies on bulk cargo
`Efforts on to restore flights from Vizag by Saturday'
TN Tourism Dept plans road shows

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line